Los Angeles Capital Management LLC Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Los Angeles Capital Management LLC decreased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 47.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,940 shares of the company’s stock after selling 24,923 shares during the period. Los Angeles Capital Management LLC’s holdings in Denali Therapeutics were worth $814,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after acquiring an additional 1,847 shares during the last quarter. CWM LLC lifted its position in shares of Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after purchasing an additional 654 shares during the last quarter. Assetmark Inc. grew its stake in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Denali Therapeutics in the first quarter valued at $147,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Activity

In other news, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This represents a 50.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,578 shares of company stock valued at $2,474,440 in the last three months. 7.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DNLI has been the subject of several analyst reports. Bank of America upped their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Denali Therapeutics in a research note on Thursday, November 7th. JPMorgan Chase & Co. reduced their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Citigroup increased their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Wedbush cut their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $25.05 on Friday. The stock has a fifty day moving average price of $28.20 and a 200 day moving average price of $23.97. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33. The company has a market cap of $3.61 billion, a PE ratio of -9.08 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. Analysts anticipate that Denali Therapeutics Inc. will post -2.69 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.